Press releases

Company's third-generation drug-eluting stents now available in rapidly growing market

Company will participate in the healthcare conference on March 2. Learn how to tune in.

New products expand treatment options for healthcare providers

Scholarship Fund Honors Company's Late Chief Medical and Scientific Officer

Journal of American College of Cardiology sub-analysis showed women received a greater clinical benefit from cardiac resynchronization therapy defibrillators (CRT-Ds) than men

New system integrates market-leading Renegade HI-FLO Microcatheter with high-torque Fathom-16 Steerable Guidewire for peripheral embolization procedures

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2010, as well as net...

Complaint involves Guidant's conduct leading to its recalls of ICDs in 2005, before Boston Scientific’s 2006 acquisition of Guidant

Procedure performed as part of BLOCk-CTI clinical trial evaluating treatment of Type 1 atrial flutter

PLATINUM China trial to support Chinese regulatory approval of next-generation platinum chromium stent

Fourth-generation stent features bioabsorbable polymer and everolimus drug coating

Distribution agreement will allow Company to expand the service it offers customers in Japan

A live webcast and archived replay of this call will be available

Innovative left atrial appendage closure device offers alternative for patients with atrial fibrillation and strengthens Company's position in emerging structural heart markets

ORION clinical trial designed to evaluate EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease

Boston Scientific Corporation (NYSE: BSX) today announced it has acquired Intelect Medical, Inc., a development-stage company located in...

Article reported on a study that found about 20 percent of patients who received an implantable cardioverter defibrillator (ICD) did not meet evidence-based guidelines

Acquisition brings Boston Scientific the first fully repositionable device for percutaneous aortic valve replacement to treat severe aortic stenosis

Company prepays $600 million of debt

Company will participate in the conference on January 11, 2011. A live webcast and replay will be available.

Distinguished leader brings broad range of expertise in science, technology, business, education and government

Patients experienced a 50 percent relative reduction in risk of death compared to in-clinic follow-up

Company will participate in the conference on December 1, 2010. A live webcast and replay will be available.

Innovative percutaneous aortic valve replacement system provides entry into emerging market of structural heart disease

INCEPTA™, ENERGEN™ and PUNCTUA™ designed to advance patient care with options to expand appropriate therapy, optimize ventricular pacing and manage heart failure

Awards recognize breakthrough products and technologies that represent a significant leap forward in their respective categories

Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention

Company's November 19, 2010 meeting will be simultaneously webcast; learn how to tune in live or access the replay.

Company implants its first Deep Brain Stimulation device designed to treat Parkinson's

Boston Scientific Corporation (NYSE: BSX) today announced that its newly acquired subsidiary, Asthmatx, Inc., presented two-year...

Proceeds to allow Company to invest in future growth opportunities while also reducing overall debt leverage

Acquisition brings the Alair® Bronchial Thermoplasty System, the first device-based asthma treatment approved by the FDA

Company's fully covered metal stent now approved for use in treating benign biliary strictures

Latest innovation in plastic biliary stent technology includes features for enhanced deliverability, efficiency and procedural control

CEO Ray Elliott notes financial results reflect “strong operating performance despite the challenges facing our industry.”

Major advance in guidewire technology for challenging peripheral interventions

Company will webcast its conference call on Tuesday, October 19. Learn how to tune in or watch the replay.

MADIT II eight-year outcomes analysis shows that one life is saved for every eight patients who receive an ICD

Largest randomized trial to compare the use of drug-eluting stents to bare-metal stents for AMI patients

Company presents one-year clinical data at TCT on its platinum chromium paclitaxel-eluting coronary stent from PERSEUS trial

Results of TAXUS ATLAS clinical program presented at TCT

Nine-month results from PLATINUM clinical program presented at TCT

Indications are important additions, especially as diabetes prevalence continues to increase worldwide

Offers first FDA-approved non-drug procedure for the treatment of severe asthma

FDA approval is based on results from the Company's landmark MADIT-CRT trial

Company to present clinical data on its platinum chromium PROMUS® Element™ and TAXUS® Element™ Coronary Stent Systems

Company to participate in the September 14th conference in New York City; live webcast and replay will be available

Presentations to feature Boston Scientific's pelvic floor reconstruction systems and mid-urethral sling systems

Resolution "marks a major milestone in our journey of continuous quality improvement," said Ray Elliott, President and Chief Executive Officer

EVOLVE trial to evaluate Company's fourth-generation SYNERGY™ drug-eluting coronary stent

Company now offers pain specialists the most comprehensive portfolio of SCS percutaneous leads

Company to participate in the August 5th conference in New York; live webcast and replay will be available

Company expands market-leading family of neurovascular stents

"I am proud of the way the organization executed in a number of key areas during the quarter," said Ray Elliott, President and CEO

Trial data to help develop a clinical alert that identifies the early onset of worsening heart failure

Company to webcast its conference call with Q2 2010 financial results and business highlights on July 21

Two new splitters allow multi-site placement of up to four spinal cord stimulation leads

Refinancing to help strengthen Company’s capital structure and provide enhanced capacity to fund acquisitions and other investments in technologies

Longer balloons provide physicians more options for treating peripheral artery disease

Women experienced a 70 percent reduction in heart failure events compared to a 35 percent reduction for men

Company to participate in the healthcare conference on June 24 in Boston; live webcast and replay will be available

Presentations to include results of the MADIT-CRT trial and the ALTITUDE clinical science program

CE Mark approval includes specific indication for treatment of diabetic patients

Company to participate in the June 16th conference in Los Angeles; live webcast and replay will be available

Randomized study of nearly 3,000 patients to evaluate Company's third-generation drug-eluting stent technology

Next-generation balloon catheter technology catheter developed specifically to address physicians' needs in optimizing coronary stent deployment

Company's iLab® Ultrasound Imaging System compatible with leading X-ray systems

Presentations to include analyses from SYNTAX trial, as well as clinical data supporting the performance of drug-eluting stents

Company expands Sterling line of peripheral angioplasty balloon catheters to include long balloons designed for below-the-knee procedures

Next-generation system strengthens Company's endometrial ablation portfolio for the treatment of menorrhagia

ACUITY Break-Away™ Lead Delivery System designed to place leads in veins of varying sizes, including difficult-to-access veins

Approval includes specific indication for treatment of diabetic patients

Upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data

Presentations will provide new insights for physicians who treat patients with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds)

Results of study using Boston Scientific's WallFlex® Duodenal Stent presented at Digestive Disease Week®

EVIDENCE Trial to study Boston Scientific's Precision Plus™ Spinal Cord Stimulator System

Positive results to be presented for SpyGlass® Direct Visualization System, Radial Jaw® 4 Biopsy Forceps and WallFlex® Duodenal Stents

Educational forum includes lab training sessions and online community for urogynecologists, urologists and surgical gynecologists

Agreement relates to product advisories issued in 2005, before Boston Scientific acquired Guidant

Company records $1.8 billion goodwill impairment charge

Major advance in guidewire technology provides exceptional torque and flexibility for coronary procedures

A live webcast and replay of the January 11, 2011 conference will be available. Learn how to tune in.

A live webcast and replay of the May 4, 2011 conference will be available

Exclusive agreement promotes access to testing solutions for female urinary incontinence

Company is positioned to fully meet customer demand for COGNIS and TELIGEN within 24 hours

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31, 2010...

Company's CRT-Ds recommended for asymptomatic and mild heart failure patients

Trials to evaluate small vessel and long lesion versions of platinum chromium PROMUS® Element™ Stent System

Boston Scientific applies to FDA for expanded indications for TAXUS Express and TAXUS® Liberte® Stents in AMI patients

Analysis of the data presented at the American College of Cardiology Annual Scientific Sessions

Manufacturing process changes were not submitted for FDA approval; no indication that changes pose any risk to patient safety

First and only premounted, balloon-expandable stent approved specifically for use in iliac arteries

Clinical data presentations to include 12-month results for third-generation TAXUS® Element™ drug-eluting stent

A webcast of the March 2 session will be available. Learn how to tune in live or watch the replay

Article reported a case summary of a patient who had been implanted subcutaneously with a Cognis cardiac resynchronization therapy defibrillator

New structure, leadership team and targeted portfolio changes will focus on sales excellence and cost effectiveness

"We delivered a quarter in line with expectations," said Ray Elliott, President and CEO

Settles three patent disputes with Johnson & Johnson (J&J) that date back to 2003

The patents relate to coatings (drug and polymer) for drug-eluting stents

Boston Scientific will webcast its February 11 conference call with financial results and business highlights for Q4 and FY 2009. Learn how to tune in.